https://www.selleckchem.com/pr....oducts/bgb-283-bgb28
Significant difference between the tested groups for most of studied parameters was found as soon as 12 or 24 hours after initiation of administration in favour of active arm and was the most prominent on days 3 and 4. Significant decrease in the total score of symptoms severity was achieved on day 4 and extended to the end of study. There were no dif-ferences in the adverse events between the groups and the tested product demonstrated excellent safety profile. This study is a clinical confirmation of well documented antiviral ac
Like
Comment
Share
